Lupin

2,009.70
+54.30
(2.78%)
Market Cap
91,751.03 Cr
EPS
42.05
PE Ratio
31.14
Dividend Yield
0.41 %
Industry
Healthcare
52 Week High
2,402.90
52 Week Low
1,493.30
PB Ratio
5.71
Debt to Equity
0.28
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from31 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+54.84 %
+54.84 %
Hold
Hold+32.26 %
+32.26 %
Sell
Sell+12.90 %
+12.90 %

Company News

View All News
Caret
positive
Lupin Healthcare UK Acquires Renascience Pharma for £12.3 MillionToday
Lupin's UK subsidiary, Lupin Healthcare UK, has acquired Renascience Pharma for £12.3 million. This strategic acquisition aims to expand Lupin's specialty pharmaceutical portfolio in the United Kingdom market.
neutral
Lupin Ltd. Block Trade: 201,611 Shares Traded for Rs. 40.48 CroresToday
A significant block trade occurred on the National Stock Exchange (NSE) involving Lupin Ltd. shares. Approximately 201,611 shares were traded at a price of Rs. 2007.75 per share, totaling Rs. 40.48 Crores in value.
neutral
Lupin to Transfer API R&D Division to Lupin Manufacturing Solutions2 days ago
Lupin Limited has announced the transfer of its Active Pharmaceutical Ingredients (API) Research and Development division to Lupin Manufacturing Solutions. This move suggests a strategic restructuring within the company, potentially aimed at optimizing research and manufacturing processes.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,713.65
#1 4,11,162.04
34.52
#1 49,887.20
12.06
#1 9,648
13.77
50.47
5,666.00
1,50,414.50
71.26
8,184.00
0.89
1,600
#1 64.53
46.20
1,452.35
1,17,293.96
23.38
26,520.70
14.17
4,155
47.38
45.27
3,207.10
1,08,542.84
57.83
10,785.70
11.59
1,656
13.54
55.87
2,421.90
99,922.39
49.65
10,615.60
19.57
1,942
-16.38
55.89
1,150.00
95,962.37
#1 17.90
28,905.40
12.36
5,578
1.69
45.11
2,009.70
#7 91,751.03
#5 31.14
#5 20,141.50
#1 19.94
#7 1,936
#3 38.82
47.61
891.15
89,670.54
19.47
19,831.50
13.82
3,831
29.92
44.76
1,157.85
67,248.12
18.70
29,559.20
17.55
3,169
-10.04
52.27
29,540.90
62,772.35
48.26
6,097.20
10.80
1,201
16.01
44.78
Growth Rate
Revenue Growth
19.94 %
Net Income Growth
332.34 %
Cash Flow Change
92.30 %
ROE
277.31 %
ROCE
143.65 %
EBITDA Margin (Avg.)
75.22 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
3,071
3,157
3,250
3,417
4,144
4,424
4,243
4,511
4,209
3,839
3,952
3,929
4,125
3,960
4,122
3,872
3,922
3,922
4,007
3,844
4,084
3,513
3,807
3,939
3,808
4,265
4,076
4,122
3,880
3,610
4,106
4,263
4,368
4,765
4,980
5,109
4,924
5,582
5,539
5,672
Expenses
2,289
2,331
2,667
2,702
2,883
3,157
3,260
3,264
3,472
3,104
3,099
3,287
4,789
3,329
3,401
3,608
3,107
3,131
3,788
3,629
3,320
3,040
3,254
3,239
3,066
3,306
5,415
3,791
3,615
3,512
3,693
3,790
3,852
3,958
4,121
4,160
3,964
4,359
4,332
4,412
EBITDA
783
825
583
715
1,261
1,268
983
1,246
737
735
853
642
-665
631
721
264
814
791
219
215
763
473
553
700
742
960
-1,339
331
265
98
414
473
515
807
859
950
960
1,223
1,207
1,261
Operating Profit %
25 %
24 %
16 %
19 %
30 %
27 %
23 %
26 %
17 %
18 %
20 %
16 %
-20 %
12 %
13 %
6 %
18 %
18 %
1 %
2 %
12 %
12 %
14 %
17 %
18 %
22 %
-35 %
7 %
6 %
3 %
10 %
11 %
11 %
17 %
17 %
18 %
19 %
21 %
21 %
21 %
Depreciation
107
101
116
122
149
203
211
231
267
261
272
280
273
259
266
219
219
250
253
253
214
215
213
244
216
209
919
203
327
193
204
220
264
235
248
257
457
248
257
272
Interest
3
7
24
10
31
35
29
48
41
44
48
54
59
69
74
79
84
84
83
89
107
44
34
31
32
34
34
33
42
43
55
84
93
86
81
74
71
68
71
67
Profit Before Tax
697
792
581
781
1,170
1,156
822
1,045
520
494
611
383
-941
384
441
93
591
518
-54
-73
496
273
360
525
518
751
-2,205
167
-85
2
210
246
259
559
630
736
498
993
1,055
1,071
Tax
136
224
158
255
417
273
159
410
137
137
154
161
-163
181
173
245
294
216
70
767
105
164
147
84
54
202
-110
-382
427
89
75
89
16
106
134
117
130
188
195
212
Net Profit
561
568
422
526
753
883
663
636
384
357
457
222
-778
203
269
-152
296
303
-123
-840
391
109
214
441
464
548
-2,095
549
-512
-87
135
158
242
453
495
619
368
806
860
859
EPS in ₹
12.17
12.65
9.34
11.67
16.63
19.57
14.69
14.04
8.42
7.93
10.07
4.91
-17.33
6.40
5.88
-3.37
6.55
6.69
-2.72
-18.56
8.64
2.36
4.66
9.67
10.15
11.96
-46.22
12.01
-11.40
-1.96
2.85
3.38
5.19
9.94
10.76
13.47
7.89
17.58
18.70
18.75

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
Fixed Assets
4,368
8,717
11,033
10,362
11,087
7,938
7,881
7,382
8,355
8,878
Current Assets
7,832
9,887
11,953
12,210
13,854
15,413
13,986
12,458
12,451
13,448
Capital Work in Progress
576
2,702
2,133
2,598
1,640
940
1,066
1,146
1,238
773
Investments
1,656
16
2,136
262
2,296
2,374
2,455
900
517
1,075
Other Assets
6,538
11,189
11,305
13,084
12,928
13,732
12,209
12,393
12,846
13,272
Total Liabilities
13,138
22,625
26,607
26,305
27,949
24,984
23,610
21,821
22,956
23,997
Current Liabilities
3,729
5,061
6,121
5,096
6,130
9,225
8,436
8,498
9,265
8,502
Non Current Liabilities
510
6,368
6,955
7,593
8,030
3,178
1,316
1,101
1,148
1,122
Total Equity
8,898
11,196
13,532
13,617
13,789
12,581
13,858
12,222
12,543
14,374
Reserve & Surplus
8,784
11,073
13,407
13,487
13,652
12,446
13,712
12,062
12,374
14,199
Share Capital
90
90
90
90
91
91
91
91
91
91

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
1,502
-1,315
2,019
729
-872
1,685
-1,303
87
273
-248
Investing Activities
-1,034
-6,769
-2,527
470
-3,283
1,107
-1,240
1,292
-1,287
-1,712
Operating Activities
2,733
-382
4,114
1,751
1,666
1,469
1,822
367
1,897
3,648
Financing Activities
-197
5,836
433
-1,492
744
-891
-1,885
-1,572
-337
-2,184

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
46.86 %
46.84 %
46.83 %
46.81 %
46.78 %
47.10 %
47.11 %
47.10 %
47.08 %
47.07 %
47.05 %
47.04 %
47.01 %
46.98 %
46.96 %
46.95 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
16.11 %
18.28 %
19.32 %
21.50 %
22.04 %
DIIs
22.08 %
21.68 %
24.38 %
24.76 %
26.84 %
26.82 %
27.54 %
29.38 %
29.21 %
28.98 %
29.42 %
29.73 %
27.76 %
26.78 %
25.09 %
24.74 %
Government
0.29 %
0.28 %
0.28 %
0.28 %
0.29 %
0.29 %
0.00 %
0.00 %
0.00 %
0.00 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
Public / Retail
10.02 %
9.91 %
10.18 %
9.99 %
8.53 %
8.59 %
8.41 %
8.06 %
7.86 %
7.06 %
6.24 %
5.87 %
5.70 %
5.65 %
5.29 %
5.17 %
Others
20.75 %
21.29 %
18.34 %
18.16 %
17.57 %
17.19 %
16.94 %
15.45 %
15.85 %
16.89 %
17.27 %
1.23 %
1.23 %
1.26 %
1.15 %
1.10 %
No of Share Holders
0
2,93,782
3,02,292
3,61,288
3,61,862
3,78,547
3,82,828
3,78,011
3,60,677
3,22,678
2,89,074
2,81,542
2,80,248
2,88,537
2,79,280
2,81,988

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 7.5 5 5 6 6.5 4 4 8 0.00
Dividend Yield (%) 0.00 1.02 0.68 0.85 0.59 0.87 0.61 0.25 0.39 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Acquisition4 hours ago
Announcement under Regulation 30 (LODR)-Restructuring2 days ago
Announcement under Regulation 30 (LODR)-Restructuring2 days ago
Board Meeting Outcome for Outcome Of The Board Meeting Held On March 31 2025.2 days ago
Closure of Trading Window5 days ago
Announcement under Regulation 30 (LODR)-Change in Management5 days ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 21, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSMar 21, 2025
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 20, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 20, 2025
Incorporation Of A Wholly Owned Subsidiary.Mar 18, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 17, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 07, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 27, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 21, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 19, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 19, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 18, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised)Feb 12, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Integrated Filing (Financial)Feb 12, 2025
Formulation Adoption And Implementation Of Lupin Employees Stock Option Scheme 2025.Feb 12, 2025
Announcement under Regulation 30 (LODR)-AcquisitionFeb 12, 2025
Announcement under Regulation 30 (LODR)-RestructuringFeb 12, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 12, 2025
Board Meeting Outcome for Outcome Of Board Meeting - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 12, 2025
Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine-Months Ended December 31 2024.Feb 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 10, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 07, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 06, 2025
Rumour verification - Regulation 30(11)Feb 04, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 03, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 01, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 30, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 27, 2025
Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine-Months Ended December 31 2024 And Other Business Matters.Jan 27, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSJan 20, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionJan 09, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025

Technical Indicators

RSI(14)
Neutral
40.13
ATR(14)
Volatile
60.43
STOCH(9,6)
Neutral
33.22
STOCH RSI(14)
Oversold
9.27
MACD(12,26)
Bearish
-5.76
ADX(14)
Weak Trend
19.96
UO(9)
Bearish
37.80
ROC(12)
Downtrend And Accelerating
-0.66
WillR(14)
Oversold
-90.89

About Lupin

Lupin is a global pharmaceutical company producing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Founded in 1983, it operates in over 100 markets, specializing in cardiovascular, diabetology, asthma, pediatric, central nervous system, gastrointestinal, anti-infective, and NSAID therapies. Lupin is a leader in anti-TB and cephalosporins segments. The company has expanded through acquisitions and partnerships, entering markets in Japan, Germany, Australia, South Africa, and the Philippines. Lupin has manufacturing facilities in various locations and has received FDA approvals for multiple generic drugs. The company has also launched innovative products and entered strategic alliances with other pharmaceutical companies for drug development and marketing.
Chairperson NameM D Gupta